FOLH1 and prostate neoplasm: Thus, although PSMA-617 and PSMA-I&T show similar binding characteristics on prostate tumors, our results indicate that PSMA-I&T has a less favorable tumor-to-kidney ratio than PSMA-617 as a higher binding to healthy organs may lead to an increased risk of toxicity.